Barclays
ESLA icon

Barclays’s Estrella Immunopharma ESLA Stock Holding History

Barclays’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131 Buy
+126
New +$165 ﹤0.01% 5165

Other funds holding ESLA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Barclays's ESLA Position: Q2 2026 in Review

Barclays opened a new position in Estrella Immunopharma (ESLA) in Q2 2026: 126 shares worth $131. The stake represents ﹤0.01% of the portfolio and ranks #5165 among its holdings.

15 funds tracked by Wall St. Rank hold ESLA as of Q2 2026.

  • Barclays held 126 shares of Estrella Immunopharma worth $131 as of Q2 2026.
  • Estrella Immunopharma was a new Barclays position in Q2 2026.
  • Estrella Immunopharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5165 holding.
  • 15 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.